SRXN1 and neoplasm: Indeed, this tumor expressed six of the NRF2 targets (CES1, CYP4F1, GSTM3, ARK1C1/3/4, AKR1C2, SRXN1, and PTGR1) more than 16-fold above their respective mean expressions for the entire cohort and 24 proteins more than 4-fold above their means (Fig. 5, C and E).